Add BrightSurf on Google Email

Science News for June 4, 2017


New drug shows durable efficacy across diverse pediatric and adult cancers

A new cancer medicine, larotrectinib, has demonstrated compelling evidence for treating a range of advanced cancers. The therapy, which targets TRK fusion proteins, resulted in responses in 76% of patients across 17 different types of cancer. After 12 months of treatment, 79% of responding patients remained progression-free.

SourceAmerican Society of Clinical Oncology·JournalJournal of Clinical Oncology·DateJun 4, 2017

Two combination therapies shrink melanoma brain metastases in more than half of patients

Researchers at MD Anderson Cancer Center present two combination therapies that significantly shrink metastatic brain tumors in over half of patients with stage IV melanoma. The trials demonstrate the feasibility of conducting clinical trials for these patients and offer new hope for those with brain metastases.

SourceUniversity of Texas M. D. Anderson Cancer Center·JournalThe Lancet Oncology·DateJun 4, 2017